MET and neoplasm: To test this hypothesis, we orthotopically micro-injected HCT-116-luc and HT-29-luc cells into hHGF KI SCID mice as described above, and then randomly assigned tumor-bearing animals to the following arms: no treatment; 15 mg/kg bevacizumab; 10 mg/kg tivozanib; 40 mg/kg JNJ-38877605 (a MET-selective small molecule tyrosine kinase inhibitor) [30]; 20 mg/kg ficlatuzumab (a HGF-neutralizing antibody) [35]; 15 mg/kg bevacizumab plus 40 mg/kg JNJ-38877605; 10 mg/kg tivozanib plus 40 mg/kg JNJ-38877605; and 10 mg/kg tivozanib plus 20 mg/kg ficlatuzumab.